血府逐瘀胶囊对重度血瘀证患者经皮冠状动脉介入治疗术后氯吡格雷抵抗的调节作用

黄瑾; 李璐奕; 祁炜罡; 黄瑛; 曾颖; 唐帆

doi:10.3969/j.issn.1006-0111.2018.06.012

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

重要提示

《药学实践与服务》杂志不接收生物战剂、毒剂相关内容的稿件。对于涉军信息类论文如需投稿，请务必投稿前电话或邮箱咨询。联系电话：021-81871323，邮箱：yxsjzzs@163.com。敬请谅解，谢谢配合！

《药学实践与服务》编辑部

重要通知

《药学实践与服务》杂志目前不收取审稿费、版面费、加急费等费用，如收到邮件声称是编辑部X编辑，要求加作者微信的，或填写编委登记申请表的，请谨防诈骗！

编辑部用于作者校稿时微信绑定的邮件是通过官方邮箱：yxsjzzs@163.com发送的，标题是《药学实践与服务》XML数字出版服务微信绑定，请区分开！如有疑虑，请联系编辑部，电话：021-81871323。

《药学实践与服务》编辑部

血府逐瘀胶囊对重度血瘀证患者经皮冠状动脉介入治疗术后氯吡格雷抵抗的调节作用

黄瑾, 李璐奕, 祁炜罡, 黄瑛, 曾颖, 唐帆

文章导航 > 药学实践与服务 > 2018 > 36(6): 533-535,546

黄瑾, 李璐奕, 祁炜罡, 黄瑛, 曾颖, 唐帆. 血府逐瘀胶囊对重度血瘀证患者经皮冠状动脉介入治疗术后氯吡格雷抵抗的调节作用[J]. 药学实践与服务, 2018, 36(6): 533-535,546. doi: 10.3969/j.issn.1006-0111.2018.06.012

引用本文:

HUANG Jin, LI Luyi, QI Weigang, HUANG Ying, ZENG Ying, TANG Fan. Regulating effect of Xuefuzhuyu capsule on clopidogrel resistance in patients with severe blood stasis syndrome after PCI operation[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 533-535,546. doi: 10.3969/j.issn.1006-0111.2018.06.012

Citation:

HUANG Jin, LI Luyi, QI Weigang, HUANG Ying, ZENG Ying, TANG Fan. Regulating effect of Xuefuzhuyu capsule on clopidogrel resistance in patients with severe blood stasis syndrome after PCI operation[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 533-535,546. doi: 10.3969/j.issn.1006-0111.2018.06.012

血府逐瘀胶囊对重度血瘀证患者经皮冠状动脉介入治疗术后氯吡格雷抵抗的调节作用

doi: 10.3969/j.issn.1006-0111.2018.06.012

1.
上海中医药大学附属岳阳中西医结合医院药学部, 上海 200437;上海市浦东新区人民医院药剂科, 上海 201299
2.
上海市浦东新区人民医院药剂科, 上海 201299
3.
上海市浦东新区人民医院心内科, 上海 201299

基金项目: 浦东新区卫生系统学科带头人培养计划（PWRd-2014-11）；浦东新区示范中药药剂学科（示范中药房）建设项目（PDZYXK-2-2013003）

Regulating effect of Xuefuzhuyu capsule on clopidogrel resistance in patients with severe blood stasis syndrome after PCI operation

1.
Department of Pharmacy, Yueyang Hospital of Integrated Traditional Chinese and Western medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China;Department of Pharmacy, Pudong New Aera People's Hospital, Shanghai 201299, China
2.
Department of Pharmacy, Pudong New Aera People's Hospital, Shanghai 201299, China
3.
Department of Cardiology, Pudong New Aera People's Hospital, Shanghai 201299, China

摘要: 目的观察血府逐瘀胶囊联合氯吡格雷治疗氯吡格雷抵抗患者的效果，评价其改善氯吡格雷抵抗作用的效果。方法经皮冠状动脉介入治疗（PCI）术后氯吡格雷抵抗患者80人，随机分组，分别给予3种药物治疗方案：A组用国产氯吡格雷（泰嘉）加用血府逐瘀胶囊；B组使用进口氯吡格雷（波立维）；C组用国产氯吡格雷（泰嘉）加用西洛他唑，连续3个月，采用血栓弹力图法检测干预后血小板抑制率。并随访患者半年，观察临床不良事件的发生率。结果治疗3个月后，各组抑制率均有所提高，且均有显著差异（P<0.05）。A组对血小板抑制的有效率达40%，优于C组（33.33%），与B组相当（40.74%）。对阿司匹林、氯吡格雷均不敏感的患者换用进口波立维对提高血小板抑制效果更佳；仅对氯吡格雷不敏感的患者加用血府逐瘀胶囊对血小板抑制有协同作用。随访半年后发现，联合使用血府逐瘀胶囊的时间延长可能会增强血小板抑制的效果，但并不增加出血及凝血功能异常等风险。结论血府逐瘀胶囊对提高血小板抑制率有一定的作用，同时对出血风险影响较小。
- 血府逐瘀胶囊 /
- 血瘀证 /
- 氯吡格雷抵抗 /
- 冠状动脉粥样硬化
Abstract: Objective To observe and evaluate the regulating effect of Xuefuzhuyu capsule combined with clopidogrel on clopidogrel resistance. Methods After PCI operation, 80 patients with clopidogrel resistance were randomly divided into three different treatments,A:clopidogrel (Tai Jia) combined with Xuefuzhuyu capsule; B:clopidogrel (Plavix); C:clopidogrel (Tai Jia) combined with cilostazol.)After three months of continuous medication, and the inhibition rate of platelet aggregation was detected by thromboela-stogram(TEG).The patients were followed up for half a year to observe the incidence of adverse events. Results After three months of treatment, the inhibition rates of the three groups were improved(P<0.05).The effective rate of platelet inhibition in group A was 40% (10/25), which was higher to group C (33.33%), and which was equivalent to group B (40.74%). The effect of platelet aggregation inhibition was better in patients who were not sensitive to aspirin and clopidogrel and then with imported Plavix. And the treatment group of clopidogrel combined with Xuefuzhuyu capsule had a synergistic effect on platelet aggregation inhibition for clopidogrel insensitive patients. After six months' follow-up, it was found that the platelet inhibition was enhanced but the bleeding risk and abnormal coagulation function was not increased after prolonged using of Xuefuzhuyu capsule. Conclusion Xuefuzhuyu capsule had a certain effect on improving the inhibition rate of platelet aggregation, which had little effect on the risk of bleeding.
- Xuefuzhuyu capsule /
- blood stasis syndrome /
- clopidogrel resistance /
- coronary atherosclerosis

[1]	VLACHOJANNIS GJ, DIMITROPOULOS G, ALEXOPOULOS D.Clopidogrel resistance:current aspects and future directions[J]. Hellenic J Cardiol,2011,52(3):236-245.
[2]	余长永,张勇,邹建军,等.氯吡格雷抵抗原因及对策的研究进展[J].中国临床药理学与治疗学,2009,14(10):1168-1173.
[3]	陈慧,严威,吴小盈,等. 血瘀证CYP2C19基因多态性与氯吡格雷抵抗和PCI术预后的关系[J]. 中国中西医结合杂志,2010,30(12):1245-1249.
[4]	张文将,邓冰湘. 血府逐瘀汤抗动脉血栓形成及其作用机制的研究进展[J]. 湖南中医药大学学报,2013,33(4):102-104.
[5]	王阶,陈可冀,翁维良,等. 血瘀证诊断标准的研究[J]. 中西医结合杂志,1988,8(10):585-589.
[6]	陈可冀, 史载祥. 实用血瘀证学[M]. 北京:人民卫生出版社,1999:17-23.
[7]	陈伯钧,潘宗奇,苏学旭,等.冠心病介入治疗前后中医证型变化的研究[J].中国中西医结合杂志,2007,27(8):689-691.
[8]	褚福永,王阶,孙晓伟,等. 血府逐瘀胶囊改善不稳定型心绞痛介入术后血瘀证患者近期生活质量的随机双盲对照试验[J]. 中西医结合学报,2009,7(8):729-735.
[9]	涂金生,黄春兰.氯吡格雷对非ST段抬高冠脉综合征患者炎性因子及预后的影响[J].临床合理用药杂志,2015,8(3):84-85.

[1]	孟盼盼, 宋慕格, 杨世超, 陈克明, 杨中铎, 马慧萍. 基于Keap1/Nrf2/HO-1信号通路研究利舒康胶囊对高原缺氧小鼠学习记忆障碍的改善作用 . 药学实践与服务, 2026, 44(1): 26-31, 52. doi: 10.12206/j.issn.2097-2024.202303006
[2]	张梦迪, 邱海莹, 王广云, 吴燕. 基于网络药理学和体外实验探究参红胶囊防治高原反应的作用机制 . 药学实践与服务, 2026, 44(): 1-10. doi: 10.12206/j.issn.2097-2024.202405056
[3]	张文静, 付慧, 郭小彬, 郭浩. 激活α7nAChR改善氯化钙诱导的小鼠腹主动脉瘤损伤研究 . 药学实践与服务, 2026, 44(6): 1-8. doi: 10.12206/j.issn.2097-2024.202409045
[4]	戴博, 王芳, 徐方楚, 周敏, 袁海龙, 杨志晖. 疏肝通络胶囊有效成分的鉴别和含量测定 . 药学实践与服务, 2026, 44(7): 358-361, 382. doi: 10.12206/j.issn.2097-2024.202405048
[5]	华俊杰, 朱敏, 张鹰楠, 卢光照, 张翮. 氟马西尼舌下喷雾剂在比格犬体内的药动学研究 . 药学实践与服务, 2026, 44(): 1-4. doi: 10.12206/j.issn.2097-2024.202503042
[6]	周小婷, 段禹, 李星源, 刘琴, 刘爱军. 中药治疗高尿酸血症的肾保护作用研究进展 . 药学实践与服务, 2026, 44(4): 167-172. doi: 10.12206/j.issn.2097-2024.202507029
[7]	何琳, 成彦琼, 赵娟娟, 陆蕙兰, 杨骏, 陈方剑. 血通胶囊降血脂以及肝脏保护作用研究 . 药学实践与服务, 2026, 44(6): 289-295, 321. doi: 10.12206/j.issn.2097-2024.202502015
[8]	余小翠, 王习文, 张贵英, 徐君伟, 祝雨薇, 胡丹. 麝香接骨胶囊的HPLC特征图谱的研究及7种成分含量测定 . 药学实践与服务, 2025, 43(8): 395-399. doi: 10.12206/j.issn.2097-2024.202307059
[9]	陈莹, 许子华, 胡北, 崔亚玲, 高欢, 吴琼. 通便灵胶囊治疗便秘的药效与机制研究 . 药学实践与服务, 2025, 43(1): 10-16. doi: 10.12206/j.issn.2097-2024.202404008
[10]	孟园园, 吴芸杨, 陈婷如, 顾秦五风, 杨延龙. 九味永安颗粒联合西替利嗪治疗湿疹湿热蕴肤证的临床疗效观察 . 药学实践与服务, 2025, 43(6): 298-302. doi: 10.12206/j.issn.2097-2024.202407045
[11]	段禹, 刘爱军. 活血化瘀法治疗血管性痴呆的研究进展 . 药学实践与服务, 2025, 43(4): 151-155, 173. doi: 10.12206/j.issn.2097-2024.202408045
[12]	陈方剑, 赵娟娟, 叶侃倜, 孙煜昕, 刘继勇, 杨骏. 血通胶囊提取工艺优化及质量控制研究 . 药学实践与服务, 2025, 43(2): 82-86, 91. doi: 10.12206/j.issn.2097-2024.202409003
[13]	李清, 郭宜银, 陈颖, 瞿发林, 董文燊, 戈煜. 夜宁胶囊对小鼠镇静催眠作用及其机制的研究 . 药学实践与服务, 2024, 42(8): 346-349. doi: 10.12206/j.issn.2097-2024.202211047
[14]	张修平, 田家盛, 王道鑫, 李佳鑫, 王品, 缪朝玉. MT-1207对小鼠血糖、血脂和动脉粥样硬化的作用 . 药学实践与服务, 2024, 42(11): 487-494. doi: 10.12206/j.issn.2097-2024.202306011

点击查看大图

计量

文章访问数: 5269
HTML全文浏览量: 655
PDF下载量: 438
被引次数: 0

血府逐瘀胶囊对重度血瘀证患者经皮冠状动脉介入治疗术后氯吡格雷抵抗的调节作用

doi: 10.3969/j.issn.1006-0111.2018.06.012

1. 上海中医药大学附属岳阳中西医结合医院药学部, 上海 200437;上海市浦东新区人民医院药剂科, 上海 201299

2. 上海市浦东新区人民医院药剂科, 上海 201299

3. 上海市浦东新区人民医院心内科, 上海 201299

基金项目: 浦东新区卫生系统学科带头人培养计划（PWRd-2014-11）；浦东新区示范中药药剂学科（示范中药房）建设项目（PDZYXK-2-2013003）

收稿日期: 2018-04-08
修回日期: 2018-07-03

关键词:

血府逐瘀胶囊 /

血瘀证 /

氯吡格雷抵抗 /

冠状动脉粥样硬化

摘要: 目的观察血府逐瘀胶囊联合氯吡格雷治疗氯吡格雷抵抗患者的效果，评价其改善氯吡格雷抵抗作用的效果。方法经皮冠状动脉介入治疗（PCI）术后氯吡格雷抵抗患者80人，随机分组，分别给予3种药物治疗方案：A组用国产氯吡格雷（泰嘉）加用血府逐瘀胶囊；B组使用进口氯吡格雷（波立维）；C组用国产氯吡格雷（泰嘉）加用西洛他唑，连续3个月，采用血栓弹力图法检测干预后血小板抑制率。并随访患者半年，观察临床不良事件的发生率。结果治疗3个月后，各组抑制率均有所提高，且均有显著差异（P<0.05）。A组对血小板抑制的有效率达40%，优于C组（33.33%），与B组相当（40.74%）。对阿司匹林、氯吡格雷均不敏感的患者换用进口波立维对提高血小板抑制效果更佳；仅对氯吡格雷不敏感的患者加用血府逐瘀胶囊对血小板抑制有协同作用。随访半年后发现，联合使用血府逐瘀胶囊的时间延长可能会增强血小板抑制的效果，但并不增加出血及凝血功能异常等风险。结论血府逐瘀胶囊对提高血小板抑制率有一定的作用，同时对出血风险影响较小。

English Abstract

Regulating effect of Xuefuzhuyu capsule on clopidogrel resistance in patients with severe blood stasis syndrome after PCI operation

1. Department of Pharmacy, Yueyang Hospital of Integrated Traditional Chinese and Western medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China;Department of Pharmacy, Pudong New Aera People's Hospital, Shanghai 201299, China

2. Department of Pharmacy, Pudong New Aera People's Hospital, Shanghai 201299, China

3. Department of Cardiology, Pudong New Aera People's Hospital, Shanghai 201299, China

Received Date: 2018-04-08
Rev Recd Date: 2018-07-03

Keywords:

Abstract: Objective To observe and evaluate the regulating effect of Xuefuzhuyu capsule combined with clopidogrel on clopidogrel resistance. Methods After PCI operation, 80 patients with clopidogrel resistance were randomly divided into three different treatments,A:clopidogrel (Tai Jia) combined with Xuefuzhuyu capsule; B:clopidogrel (Plavix); C:clopidogrel (Tai Jia) combined with cilostazol.)After three months of continuous medication, and the inhibition rate of platelet aggregation was detected by thromboela-stogram(TEG).The patients were followed up for half a year to observe the incidence of adverse events. Results After three months of treatment, the inhibition rates of the three groups were improved(P<0.05).The effective rate of platelet inhibition in group A was 40% (10/25), which was higher to group C (33.33%), and which was equivalent to group B (40.74%). The effect of platelet aggregation inhibition was better in patients who were not sensitive to aspirin and clopidogrel and then with imported Plavix. And the treatment group of clopidogrel combined with Xuefuzhuyu capsule had a synergistic effect on platelet aggregation inhibition for clopidogrel insensitive patients. After six months' follow-up, it was found that the platelet inhibition was enhanced but the bleeding risk and abnormal coagulation function was not increased after prolonged using of Xuefuzhuyu capsule. Conclusion Xuefuzhuyu capsule had a certain effect on improving the inhibition rate of platelet aggregation, which had little effect on the risk of bleeding.

引用本文:

Citation:

HUANG Jin, LI Luyi, QI Weigang, HUANG Ying, ZENG Ying, TANG Fan. Regulating effect of Xuefuzhuyu capsule on clopidogrel resistance in patients with severe blood stasis syndrome after PCI operation[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 533-535,546. doi: 10.3969/j.issn.1006-0111.2018.06.012